治疗特应性皮炎的新药——Eucrisa  

New drug for the treatment of atopic dermatitis――Eucrisa

作　　者：贺晓瑛 周婷 谢菲[2] 

机构地区：[1]华北理工大学,河北唐山063210 [2]国家应急防控药物工程技术研究中心军事医学科学院毒物药物研究所,北京100850

出　　处：《临床药物治疗杂志》2017年第5期6-9,共4页Clinical Medication Journal

摘　　要：Eucrisa是由美国安纳考尔医药公司研制的用于治疗特应性皮炎的软膏剂,2016年12月14日FDA批准其用于轻度至中度特应皮炎的外用治疗。Eucrisa的活性成分Crisaborole是磷酸二酯酶-4抑制剂,是一种含硼的小分子抗炎药,其作用机制尚未完全明确。临床研究表明,Crisaborole的疗效明显,29 d对轻至中度特应性皮炎患者的平均治愈可达到32%,且安全性高,对2岁及以上儿童和怀孕期妇女未见不良影响。Crisaborole是美国FDA在过去15年首次批准治疗特应性皮炎的新药,为特异性皮炎患者提供了一种重要的非类固醇替代疗法。笔者就该药的基本信息、作用机制、药动学、药效学、临床试验及应用等研发动态进行了概述,以期能为医院临床用药起到指导作用。Eucrisa is an ointment developed by Anacor Pharmaceuticals, Inc for the treatment of atopic dermatitis. On December 14, 2016, the FDA approved Crisaborol for topical treatment of mild to moderate atopic dermatitis in 2 years of age and older patients. The active ingredient in Eucrisa is Crisaborol, a phosphodiesterase-4 inhibitor which is also a boron-containing small molecule anti- inflammatory drug, whose mechanism is not yet fully understood.Clinical studies have shown that the effect of Crisaborol is significant which with an average cure rate of 32% for patients with mild to moderate atopic dermatitis at day 29, and with highly safety. There is no adverse effect on children aged 2 years and older and pregnant women, and there is no available data with Crisaborol in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. Crisaborol has been the first new drug for atopic dermatitis approved by FDA in the past 15 years. Crisaborol provides an important non-steroid alternative drug for patients of atopic dermatitis. In this paper, the basic information, mechanism, pharmacokinetics, pharmacodynamics, clinical trials and applications of Crisaborolwere summarized, in order to provide reference for clinical treatment.

关 键 词：特应性皮炎 Crisaborole 软膏 

分 类 号：R978.1[医药卫生—药品]